US Patent

US8865937 — Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide

Composition of Matter · Assigned to Individual · Expires 2032-05-23 · 6y remaining

Vulnerability score 9/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel crystalline forms of the compound (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide.

USPTO Abstract

The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.

Drugs covered by this patent

levomilnacipran-hydrochloride (LEVOMILNACIPRAN HYDROCHLORIDE)

Patent Metadata

Patent number: US8865937
Jurisdiction: US
Classification: Composition of Matter
Expires: 2032-05-23
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.